The kit will detect genetic mutations associated with bladder cancer.
Healthcare Technologies (Nasdaq: HCTL ) subsidiary Savyon Diagnostics, which produces clinical diagnosis tools, and ProChon Biotech , which develops fibroblast growth-factor (FGF) based therapeutics, have entered into a collaboration agreement for the development and manufacture of a genetic kit for diagnosis of mutations associated with forms of bladder cancer.
These mutations, prevalent in inherited skeletal disorders, have been linked to tumor progression and prognosis in several types of cancer.
Under the agreement, Savyon will be responsible for prototype kit development and manufacturing, and ProChon will be responsible for clinical development and retain worldwide exclusive rights for commercialization of the kit. Financial terms were not disclosed.
Prochon founder and Chief Scientific Officer, Prof. Avner Yayon said, "Developing a diagnostic kit to determine the presence of these mutations will enable more effective, personalized treatments and better hope for those suffering from bladder carcinoma."
Published by Globes [online] - www.globes.co.il - on 13 May 2002